October 2017

New Product - NovoThirteen

NovoThirteen (catridecacog (rys)) is a recombinant human coagulation factor XIII A-subunit. Factor XIII is the terminal enzyme in the blood coagulation cascade. When activated by thrombin at the site of vessel wall injury, factor XIII plays an important role in the maintenance of haemostasis through cross-linking of fibrin and other proteins in the fibrin clot. NovoThirteen is indicated for routine prophylaxis of bleeding in patients with congenital factor XIII A-subunit deficiency. NovoThirteen lyophilised powder for injection is available in a single use vial containing 2500 IU in a pack of 1.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au